Abstract
This article presents a rare case of renal metastasis from papillary thyroid carcinoma (PTC) with concurrent lung and bone metastases. Through a retrospective analysis of the patient’s diagnostic and treatment process, we aim to contribute to the development of precise treatment strategies for such rare cases, thereby improving patient prognosis.
Introduction
Thyroid cancer is one of the most prevalent malignancies in the endocrine system and represents a significant public health challenge. Its incidence has shown a rapid upward trend over the past few decades. Thyroid cancer is classified into four main pathological types: Papillary Thyroid Carcinoma (PTC), Follicular Thyroid Carcinoma (FTC), Anaplastic Thyroid Carcinoma (ATC), and Medullary Thyroid Carcinoma (MTC) (). Among these, PTC is the most common, accounting for 90% of thyroid tumors, while FTC constitutes 5% to 10% of thyroid tumors. Although many PTC patients have a favorable prognosis with a 5-year survival rate of 95%, 10%-20% of well-differentiated thyroid cancers are associated with distant metastases. Follicular thyroid cancer most commonly metastasizes to the lungs and bones, whereas papillary thyroid cancer is less frequently associated with bone metastasis. For patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer, surgical resection or stereotactic body radiotherapy is superior to systemic therapy (). Two oral multi-target tyrosine kinase inhibitors, sorafenib tosylate and lenvatinib (), are available; however, survival rates remain unfortunately low, necessitating new research approaches utilizing novel technologies ().
A 48-year-old female patient presents with a chronic oncological condition. She underwent a partial nephrectomy of the right renal space-occupying lesion in December 2024 after a tumor in the right kidney (Figures 1A, B) was detected during a routine physical examination. In her past medical history, the patient underwent a subtotal thyroidectomy in 2012 due to papillary thyroid carcinoma on the left side, with postoperative pathology confirming the diagnosis. Additionally, the patient exhibits multiple bony metastases (Figures 2, 3), and pulmonary metastases (Figures 1C, D) throughout her body. She has no history of other diseases, no family history of cancer, and no abnormal psychosocial history.
Figure 1
Figure 2
Figure 3
In October 2024, the patient presented to the orthopedic department with intermittent low back pain and was diagnosed with suspected secondary malignant tumors in multiple bones upon examination. In October 2024, the patient underwent a biopsy of bone destruction in the right pelvis, and the postoperative pathology indicated bone metastasis from thyroid cancer (Figures 4B, 5B). Subsequently, the patient received an exploratory curettage of the right pelvic tumor, microwave ablation, and bone cement filling. In November 2024, the patient underwent computed tomography (CT) - guided implantation of radioactive ¹²5I seeds into the soft tissue of the left chest wall and thoracic vertebrae. Shortly thereafter, the patient also underwent laparoscopic partial nephrectomy of the right kidney, with postoperative pathology revealing metastatic foci of papillary thyroid carcinoma within the right renal tissue (Figures 4A, 5A).
Figure 4
Figure 5
Physical Examination: No bulging was observed in the bilateral renal regions, and no tenderness or percussion pain was noted. There was no tenderness along the course of the bilateral ureters, and no tenderness was detected in the bladder area.
Discussion
Papillary thyroid carcinoma primarily metastasizes through the lymphatic system. Tumor cells can migrate via lymphatic vessels to cervical lymph nodes, including those in the central and lateral neck regions. Hematogenous spread to distant organs is less common, and it is even rarer for distant metastases to be the initial presenting symptom. Among the less common distant metastatic sites, the lungs are included. The cervical lymph nodes are the most frequent sites of metastasis (). In contrast, follicular thyroid carcinoma mainly spreads through the bloodstream. Once cancer cells enter the circulatory system, they can metastasize to distant organs. The most common distant metastatic sites are the lungs () and bones (), with other possible sites including the liver () and adrenal glands (). Medullary thyroid carcinoma also primarily metastasizes through the lymphatic system, particularly to the central and lateral cervical lymph nodes, but can also spread hematogenously. Distant metastases may involve organs such as the lungs () and liver (). Common primary tumors that metastasize to the kidneys include lung cancer (), breast cancer (), liver cancer () colorectal cancer (), and malignant melanoma ().
Here, we present a rare case of renal metastasis from papillary thyroid carcinoma. The patient presented with concurrent metastases involving the pulmonary parenchyma, skeletal system, and kidneys. Given the patient’s condition, we prioritized symptomatic treatment. The patient experienced a right gluteal mass with worsening pain, accompanied by right iliac bone destruction and a surrounding soft tissue mass. Multi-Disciplinary Treatment discussion clinical manifestations, physical examination, and imaging findings, surgical intervention was deemed appropriate. The patient subsequently underwent exploratory surgery with curettage, microwave ablation, and bone cement augmentation for the right pelvic lesion. Concurrently, due to identified destructive changes in the left 9th rib with associated soft tissue mass and radiographic evidence of metastatic involvement in the T8 vertebral body, CT-guided 125I seed implantation was performed targeting the thoracic wall soft tissue and spinal lesions. Subsequently, a laparoscopic partial nephrectomy was performed for a right renal mass to remove the kidney lesion and inhibit disease progression. Notably, as the patient had not undergone previous total thyroidectomy, Multi-Disciplinary Treatment discussion contraindicated completion thyroidectomy, thereby precluding subsequent radioactive iodine therapy. Postoperative management includes continued TSH-suppressive therapy and molecular targeted therapy with lenvatinib. During the 9-month postoperative follow-up, the patient remained clinically stable. With TgAb being negative, the serum non-stimulated thyroglobulin level decreased from 45.4 ng/mL to 4.75 ng/mL. The patient exhibited stable vital signs and maintained good neurological function.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Ethics statement
Ethical approval was not required for the studies involving humans because The case report is accompanied by the patient’s informed consent form. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
WH: Visualization, Writing – review & editing, Resources, Project administration, Writing – original draft. ZH: Visualization, Resources, Writing – review & editing. YL: Writing – review & editing. QB: Data curation, Writing – review & editing. MY: Supervision, Writing – review & editing. PY: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. Funding: Clinical Research Program of the Air Force Medical University(2023LC2325); Key R&D Project of Shaanxi Province Health Commission Scientific Research Innovation Capacity Enhancement Program(2025YF-20); Convergence Research Funding Initiative of Fourth Military Medical University (2024JC030).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AsaSL. The current histologic classification of thyroid cancer. Endocrinol Metab Clin North Am. (2019) 48:1–22. doi: 10.1016/j.ecl.2018.10.001
2
BoucaiLZafereoMCabanillasME. Thyroid cancer: A review. Jama. (2024) 331:425–35. doi: 10.1001/jama.2023.26348
3
ChenDWLangBHHMcLeodDSANewboldKHaymartMR. Thyroid cancer. Lancet. (2023) 401:1531–44. doi: 10.1016/s0140-6736(23)00020-x
4
GrimmD. Recent advances in thyroid cancer research. Int J Mol Sci. (2022) 23(9):4631. doi: 10.3390/ijms23094631
5
MalhotraGNairNMenonHGujralSAbhyankarABaghelNSet al. Bronchoalveolar carcinoma of lung masquerading as iodine avid metastasis in a patient with minimally invasive follicular carcinoma of thyroid. Clin Nucl Med. (2008) 33:26–9. doi: 10.1097/RLU.0b013e31815c50a8
6
BattaRNjoumYDeekRAwadFBakriIAMareeM. Follicular thyroid carcinoma with sternal metastasis: A case report. Int J Surg Case Rep. (2023) 109:108625. doi: 10.1016/j.ijscr.2023.108625
7
BattooAJRasoolZSheikhZAHajiAG. Follicular thyroid carcinoma presenting as solitary liver metastasis: A case report. J Med Case Rep. (2016) 10:347. doi: 10.1186/s13256-016-1140-z
8
YuntaPJPonceJLPrietoMLópez-AznarDSancho-FornosS. Solitary adrenal gland metastasis of a follicular thyroid carcinoma presenting with hyperthyroidism. Ann Endocrinol (Paris). (2001) 62:226–9.
9
Al HassanMSEl AnsariWAlaterADarweeshAAbdelaalA. Choroidal metastasis as initial presentation of aggressive medullary thyroid carcinoma with widespread mediastinal, brain, pituitary, bone, lung, and liver metastasis: case report and literature review. Int J Surg Case Rep. (2021) 87:106419. doi: 10.1016/j.ijscr.2021.106419
10
ShikareSBashirKMenonPSBapatRDTilveGH. Detection of medullary carcinoma of thyroid, with liver metastasis, using 99mtc dmsa(V) scintigraphy. J Postgrad Med. (1995) 41:12–3.
11
BaiSJBaoYGYangL. Renal pelvic metastasis from non-small cell lung cancer with renal vein thrombosis. Asian J Surg. (2022) 45:1014–5. doi: 10.1016/j.asjsur.2021.12.016
12
LakovschekICPetruEPollheimerMJRatschekMAugustinHBjelic-RadisicV. A rare case of cancer-to-cancer metastasis: breast cancer to renal cell cancer: case report and review of literature. Wien Med Wochenschr. (2019) 169:350–3. doi: 10.1007/s10354-019-0694-y
13
UchikoshiMItoTNakajimaYSugiuraIUozumiSShimozumaYet al. Simultaneous gastric, pancreatic, and renal metastasis from poorly differentiated hepatocellular carcinoma. Clin J Gastroenterol. (2024) 17:497–504. doi: 10.1007/s12328-024-01935-w
14
DoganMOzalGEkinciCUtkanGUrunYYalcinBet al. Two cases with atypical metastasis in colorectal cancer: splenic and renal metastasis. Exp Oncol. (2010) 32:277–9.
15
ShimkoMSJacobsSCPhelanMW. Renal metastasis of Malignant melanoma with unknown primary. Urology. (2007) 69:384.e9–10. doi: 10.1016/j.urology.2006.11.013
Summary
Keywords
thyroid cancer, renal metastasis, lung metastasis, bone metastasis, radioactive iodine-125 seed
Citation
Huang W, Hou Z, Lin Y, Bai Q, Yuan M and Yuan P (2025) Renal metastasis from papillary thyroid carcinoma: A rare case report. Front. Oncol. 15:1597612. doi: 10.3389/fonc.2025.1597612
Received
21 March 2025
Accepted
04 September 2025
Published
19 September 2025
Volume
15 - 2025
Edited by
Anna Perri, Magna Græcia University of Catanzaro, Italy
Reviewed by
Bin Wang, The Third People’s Hospital of Chengdu, China
Pranab Dey, Post Graduate Institute of Medical Education and Research (PGIMER), India
Updates
Copyright
© 2025 Huang, Hou, Lin, Bai, Yuan and Yuan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peng Yuan, yuanpeng834700@126.com
‡ORCID: Wen Huang, orcid.org/0009-0005-2879-9082; Zhenghui Hou, orcid.org/0009-0005-3238-6264
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.